Abstract Obtaining high levels of pure proteins remains the main bottleneck of many scientific and biotechnological studies. Among all the available recombinant expression systems, Escherichia coli facilitates gene expression by its relative simplicity, inexpensive and fast cultivation, well-known genetics and the large number of tools available for its biotechnological application. However, recombinant expression in E. coli is not always a straightforward procedure and major obstacles are encountered when producing many eukaryotic proteins and especially membrane proteins, linked to missing posttranslational modifications, proteolysis and aggregation. In this context, many conventional and unconventional eukaryotic hosts are under exploration and development, but in some cases linked to complex culture media or processes. In this context, alternative bacterial systems able to overcome some of the limitations posed by E. coli keeping the simplicity of prokaryotic manipulation are currently emerging as convenient hosts for protein production. We have comparatively produced a "difficult-to-express" human protein, the lysosomal enzyme alpha-galactosidase A (hGLA) in E. coli and in the Appl Microbiol Biotechnol (2015) 99:5863-5874 DOI 10.1007 psychrophilic bacterium Pseudoalteromonas haloplanktis TAC125 cells (P. haloplanktis TAC125). While in E. coli the production of active hGLA was unreachable due to proteolytic instability and/or protein misfolding, the expression of hGLA gene in P. haloplanktis TAC125 allows obtaining active enzyme. These results are discussed in the context of emerging bacterial systems for protein production that represent appealing alternatives to the regular use of E. coli and also of more complex eukaryotic systems.
Introduction
The deep genetic and physiological characterization, short generation time, ease of handling, established fermentation know-how and finally the capacity to accumulate foreign proteins to a high percentage of the total cellular protein content have made Escherichia coli the most widely used prokaryotic organism for recombinant protein production. However, there are disadvantages in using E. coli as an expression host. For instance, E. coli is not capable of producing eukaryotic posttranslational modifications, such as glycosylation, phosphorylation or disulphide bridge formation in the reducing cytoplasm, which can be critical for the production of folded, active proteins. Even so, several strategies can be implemented to obtain specific posttranslational modifications as the use of E. coli strains which have been engineered to maintain oxidizing conditions in the cellular milieu or to send the recombinant protein to the periplasmic space to allow cysteine bridging (Inaba 2009; Nozach et al. 2013; Prinz et al. 1997) . In addition, a N-linked protein glycosylation system has been recently identified in the human enteropathogen Campylobacter jejuni that can be transferred to E. coli (Wacker et al. 2006) , opening up the possibility of engineering recombinant products needing glycosylation for research and industrial applications.
On the other hand, some proteins, especially large and membrane proteins, simply fail to be produced in E. coli, and they occur as proteolysed species or deposited in inclusion bodies (Vallejo and Rinas 2004) . Others are subjected to premature termination of translation in the presence of repetitive DNA sequences or rare codons (Daly and Hearn 2005; Sallach et al. 2009 ) or have a low rate of internal translation initiaton (Ferreira et al. 2013; Nakamoto 2009) . A large number of studies describe the conversion of proteins accumulated in inclusion bodies into soluble forms. Mainly, these methods can be categorized into three alternative approaches. In the first one, factors influencing the amount of recombinant protein present in the insoluble fraction can be modified through careful optimization and control of the production conditions, leading to the expression of the recombinant protein in its soluble version. In this context, conventional approaches include gene expression at low temperature, use of promoters with different transcriptional strengths, modifications of growth media and the use of folding modulators (Kolaj et al. 2009 ). Alternatively, the protein can be extracted from inclusion bodies either under native or denaturing conditions (Martinez-Alonso et al. 2009 ). Finally, the target protein can be engineered to achieve soluble expression through fusion of solubility-enhancing tags (Sahdev et al. 2008; Torres et al. 2012) .
In the recent years, a novel prokaryotic expression system has been developed based on the use of the psychrophilic bacterium Pseudoalteromonas haloplanktis TAC125 by driving the expression of genes of interest by both basal or inducible promoters (Duilio et al. 2004a, b) . In addition, as was established for E. coli expression system, mutation of genes coding for proteases greatly reduces proteolysis of the recombinant protein (Parrilli et al. 2008) . The system has demonstrated to be especially useful in improving protein solubility in relation to the widely used E. coli expression system and gives higher protein yield for secreted proteins (Cusano et al. 2006; Giuliani et al. 2014; Vigentini et al. 2006) . Proteomics analysis points out the trigger factor chaperone as the main factor involved in protein folding during recombinant protein expression under cold temperatures (Piette et al. 2010) .
The human α-galactosidase A (EC 3.2.1.22; α-Gal A or GLA) is the lysosomal exoglycosidase responsible for the hydrolysis of terminal α-galactosyl moieties from various glycoconjugates. In the late 1980s, the full-length complementary DNA (cDNA) and the entire genomic sequence encoding mammalian GLA were isolated and characterized (Calhoun et al. 1985; Gotlib et al. 1996) . The 1.4-kb fulllength cDNA encodes a peptide of 429 residues, which includes a 31-residue amino-terminal signal peptide. This enzyme precursor is a glycopeptide (of approx. 55 kDa) that is processed by cleavage of the signal peptide and by oligosaccharide modifications in the Golgi and lysosomes to form the mature, active, homodimeric enzyme (approx. 100 kDa). After cleavage of the signal peptide, the glycopeptide undergoes modification of its N-linked oligosaccharide moieties in the Golgi apparatus, and then it is transported to the lysosome via the mannose-6-phosphate receptor (M6PR)-mediated pathway. Mutations in the hGLA gene resulting in deficient or absent enzymatic activity are the basis of Fabry's disease, a disorder characterized by progressive glycosphingolipid deposition in vascular lysosomes leading to early demise from renal, cardiac or cerebral vascular disease (Garman and Garboczi 2002) .
The subunits of the glycosylated mature enzyme contain four putative N-glycosylation consensus sites at positions Asn139, Asn192, Asn215 and Asn408 and five disulphide bonds between residues Cys52-Cys94, Cys56-Cys-63, Cys142-Cys172, Cys202-Cys223 and Cys378-Cys382 (Garman and Garboczi 2004; Saito et al. 2013) . The human enzyme has been purified from a variety of sources, and its physical and kinetic properties have been also characterized (Chen et al. 2000a, b; Corchero et al. 2011 Corchero et al. , 2012 Yasuda et al. 2004) . However, the hGLA obtained from prokaryotic expression systems has neither been fully characterized nor purified (Hantzopoulos and Calhoun 1987) . Therefore, the objective of this work is the production and purification of active hGLA from prokaryotic cell factories.
Material and methods

Bacterial strains and plasmids
The E. coli strains used in this work were DH5α for plasmid cloning and maintenance; BL21(DE3), Rosetta 2(DE3) and Rosetta-gami B(DE3) (Novagen) for recombinant protein expression and S17-1(λpir) were used as donor in interspecific conjugation experiments (Tascon et al. 1993) . P. haloplanktis TAC125 is a Gram-negative bacterium isolated from Antarctic seawater and is deposited and available at the Institut Pasteur Collection (CIP 108707) (Medigue et al. 2005 ). Antarctic bacteria transformation was achieved by intergeneric conjugation as previously reported (Duilio et al. 2004b) .
The four E. coli expression vectors used in this work (Fig. 1a ) are as follows: (a) pReceiver-B01-GLA (product EX-Q0172-B01, OmicsLink ORF Expression Clone), encoding a full-length version of hGLA under the control of the T7 promoter; in this vector, 6×His-tag is fused to the Nterminus of the hGLA open reading frame (ORF) for further detection and purification purposes; (b) pGEX4T2-GLA, encoding the mature form of the hGLA with a glutathione Stransferase (GST) fused at its N-terminus; a His-tag and a Tobacco etch Virus protease (TEVp) cleavage site were also added in the designed PCR oligonucleotides of the hGLA gene for purification purposes; (c) pGEX4T2-Opt-GLA, synthetic, codon optimized hGLA gene (GeneArt, Invitrogen; KF500099) cloned into pGEX4T2 as previously described; and (d) pGEX4T2-GLA-GFP, derived from pGEX4T2-GLA in which the green fluorescent protein (GFP) coding sequence was inserted into the EcoRI cloning site. Some other four expression vectors used in E. coli strains are described in Suppl. Fig. S1a .
Finally, the psychrophilic gene expression vector pPM13psDs-GLA (e) was constructed as follows: the pPM13psDs shuttle vector, containing the strong constitutive promoter PM13 (Duilio et al. 2004a) respect to a psychrophilic Shine-Dalgarno sequence and the 93-bp encoding the signal peptide of P. haloplanktis TAC125 DsbA was double digested by SalI-EcoRI. The synthetic codon optimized hGLA gene (KF500099) was double digested by SalI-EcoRI and cloned into pPM13psDs corresponding sites (Fig. 1a) .
Recombinant human GLA production and cellular fractionation
The production process in recombinant E. coli cells was performed by the Protein Production Platform (http://ibb. uab.es/ibb) of the Institute of Biotechnology and Biomedicine (IBB-UAB) and the Biomedical Networking Center (CIBER-BBN). In short, shake flask cultures were set at 37°C and 250 rpm in LB-rich medium, plus 100 μg/ mL of ampicillin for plasmid maintenance in all expression E. coli vectors. Expression of recombinant hGLA gene was induced when the absorbance at 550 nm reached values around 0.5, adding isopropyl β-D-1-thiogalactopyranoside (IPTG) at concentrations ranging from 0.1 to 1 mM. Incubation proceeded then at different temperatures of 16, 20, 25 and 37°C depending on the strain as indicated. After induction of gene expression, 1.5-mL culture samples were withdrawn at different times and soluble and insoluble fractions were separated. In short, cells were harvested by centrifugation at 5000g (at 4°C) for 15 min and resuspended in 200 μL of phosphate-buffered saline (PBS) (7.5 mM Na 2 HPO 4 , 110 mM NaCl, 2.5 mM NaH 2 PO 4 , pH 7.4) and further sonicated. Soluble and insoluble fractions were separated by centrifugation at 15,000g for 15 min at 4°C. Insoluble fractions were resuspended in PBS (same volumes than those from their respective soluble fractions). Both fractions were stored at −80°C until further analysis. P. haloplanktis TAC125 (pPM13psDs-GLA) recombinant cells were cultured in aerobic conditions at 4 and 15°C in TYP broth (16 g/L yeast extract, 16 g/L bacto tryptone, 10 g/L marine salt mix) at pH 7.5, supplemented with 100 μg/mL ampicillin, and the recombinant hGLA production and its cellular localization were evaluated in cell samples withdrawn at different growth phases. Cell pellets (corresponding to OD 600 nm =10) were resuspended in 1 mL of 50 mM TrisHCl at pH 8.0, 50 mM EDTA and disrupted by ultrasonic treatment consisting of six cycles of 30 s on/1 min off on ice. The mixture was centrifuged for 15 min at 10,000g at 4°C; the resulting supernatant and pellet were collected as soluble and insoluble fractions, respectively. Total P. haloplanktis TAC125 (pPM13psDs-GLA) cell extract was obtained by resuspending 0.5 OD 600 nm cell pellet into 400 μL of sodium dodecyl sulphate (SDS) loading dye, followed by 30 min treatment at 90°C.
The periplasmic cell extract was obtained by resuspending bacterial pellets in 1/20 of culture volume of borate buffer (200 mM Na 2 B 4 O 7 , 130 mM NaCl, 5 mM EDTA, pH 8) and incubating the mixture for 18 h at 4°C. The suspension was then centrifuged at 8000 rpm for 15 min at 4°C. The supernatant was stored as periplasmic extract, while the pellet was resuspended in 1/20 of original culture volume of SDS loading dye, followed by 30 min of treatment at 90°C and stored as cytoplasmic extract.
Recombinant protein detection
Total cell extracts, soluble, insoluble and periplasmic cell fractions were analysed by SDS-polyacrylamide gel electrophoresis (PAGE) and Coomassie staining. For Western blot studies, upon SDS-PAGE proteins were blotted onto nitrocellulose membranes, hGLA immunoreactive bands were developed using either a rabbit polyclonal anti-GLA serum from Santa Cruz Biotechnology, Inc. (α-gal A H-104: sc-25823) raised against an epitope corresponding to amino acids 316-429 at the C-terminus of the mature form of hGLA (Fig. 1b) , a rabbit polyclonal anti-GLA serum from Sigma Prestige Antibodies (product HPA000237) raised against amino acids 302-412 of the mature form of hGLA, or a monoclonal antibody anti-His-tag from GE Healthcare (product 27-471001), and the corresponding secondary antibodies. GST was detected with mouse monoclonal anti-GST antibody (Santa Cruz Biotechnology, Inc.; SC-138) and GFP with rabbit polyclonal anti-GFP antibodies (Santa Cruz Biotechnology, Inc.; SC-8334).
For comparison purposes, gels were loaded with sample volumes adjusted according to the OD of the culture. Samples for quantitative comparison were run in the same gel and processed as a set. Bands were analysed with the Quantity One analysis software (BioRad).
Protein purification GST-containing hGLA recombinant proteins were purified from Rosetta-gami B cell cultures induced at 0.1 mM IPTG for 16 h at 20°C at 250 rpm. Cell pellets were resuspended in PBS buffer (7.5 mM Na 2 HPO 4 , 110 mM NaCl, 2.5 mM NaH 2 PO 4 , pH 7.4) in the presence of EDTA-free protease inhibitors (Roche Applied Science), and cells were lysed using a French Press (Thermo FA-078A) at 1100 psi. The soluble fraction was separated by centrifugation at 15,000g for 45 min at 4°C, filtered through 0.22-μm filters and loaded onto a 1-mL GSTrap HP column (GE Healthcare, 17-5281-05). Bound GST-GLA protein was eluted with five column volumes of elution buffer (50 mM Tris-HCl and 10 mM reduced glutathione, pH 8.0). Positive fractions were collected and dialysed against 0.01 M acetic buffer (pH 4.5), and protein concentration was estimated using the Bradford method.
The pellets of E. coli or P. haloplanktis TAC125 cells containing His-tagged hGLA proteins were resuspended in buffer A (20 mM Tris-HCl pH 7.5, 500 mM NaCl and 10 mM imidazole) and cells disrupted by sonication in the presence of EDTA-free protease inhibitors (Complete, 11873580001 from Roche). The soluble cell fraction was separated by centrifugation at 15,000g for 15 min at 4°C. After filtration through 0.22-μm filters, recombinant proteins were purified by affinity chromatography in Ni 2+ columns (HiTrap Chelating HP columns, 17-0408-01 from GE Healthcare) in an ÄKTA™ Purifier (GE healthcare) fast protein liquid chromatography system. Positive fractions in elution buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl and 500 mM Imidazole) were collected and dialyzed against 0.01 M acetic buffer (pH 4.5). Protein concentration was estimated using the Bradford method.
Purified proteins were characterized by N-terminal sequencing by Edman's automated degradation using in an Applied Biosystems Procise 492 protein sequencer, and molecular weight was experimentally determined by mass spectrometry (UltraFlex MALDI-TOF mass spectrometer, Bruker Daltonics, Bremen, Germany). Both analyses were performed at the Proteomics and Bioinformatics Unit of the Scientific Technical Service, SepBioEs, of the Autonomous University of Barcelona.
Time course of TEV cleavage reaction of GST-GLA-GFP Purified GST-GLA-GFP was dialysed against reaction buffer (50 mM Tris-HCl, pH 8.0, 0.5 mM EDTA). Ten units of TEVp (Invitrogen, 12575-015) was added to 20 μg of GST-GLA-GFP and incubated at 30°C; 30-μL aliquots were removed at specified incubation times. Reaction was stopped by adding 30 μL of stop solution (125 mM Tris-HCl, pH 6.8; 4 % SDS; 1.4 M β-mercaptoethanol; 20 % (v/v) glycerol; 0.01 % bromophenol blue), and samples were stored at −20°C until gel electrophoresis analysis. Protein samples when performing hGLA activity assays were used without buffer addition after protease incubation.
Enzyme assay of α-galactosidase A activity
The enzymatic hGLA activity was assayed with 4-methylumbelliferyl α-D-galactoside (4MU-α-Gal, ref.
M7633, Sigma Chemical, St. Louis, MO) as a substrate, at a concentration of 2.46 mM in 0.01 M acetic buffer (pH 4.5). A typical 4MU-α-Gal assay was performed with a reaction mixture containing 100 μL of substrate and 25 μL of enzyme solution. Enzymatic reactions took place in agitation, at 37°C for 1 h. Reaction was stopped adding 1.25 mL of 0.2 M glycine-NaOH buffer (pH 10.4). The released 4-methylumbelliferone (4-MU) was determined by fluorescence measurement at 365 and 450 nm as excitation and emission wavelengths, respectively. Samples ranging from 5 to 500 ng/ mL of 4-MU (ref. M1381, Sigma, St. Louis, MO) in 0.2 M glycine-NaOH buffer (pH 10.4) were used as standard curve.
One unit of enzyme activity was defined as the amount of enzyme releasing 1 nmol of 4-MU per milligram of enzyme and per hour. hGLA obtained from human fibroblasts or HEK-293 T cells were used as positive controls (Corchero et al. 2011) .
Results
Recombinant expression of human GLA ORF in E. coli
Plasmid pReceiver-B01-GLA, which contains the complete ORF of hGLA gene, was transformed in E. coli BL21(DE3) and Rosetta(DE3) E. coli strains (Fig. 1a) . The Rosetta strain is able to compensate low concentrations of certain tRNAs of E. coli and to improve recombinant protein translation. It should be noticed that in the hGLA ORF, at least four critical arginine codons are present in the DNA sequence (Fig. 1b) . Strains BL21(DE3) and Rosetta(DE3), with and without the expression plasmid, were submitted to gene expression induction conditions and analysed by SDS-PAGE followed by Western blot. Nitrocellulose membranes were developed either with a polyclonal anti-GLA antibody (Sigma-Aldrich Co.) raised against an epitope corresponding to amino acids 302-412 of the hGLA protein or with the monoclonal antiHis-tag (Fig. 2a, b) . Results showed that the polyclonal antibody from Sigma and the anti-His antibody detect a main protein band corresponding to the degradation product of about 40-42 kDa (expected MW 49.6 kDa), both antibodies detecting this band as the main immunoreactive product, while samples from not transformed cells did not show any immunoreactive band. Also, both antibodies detected bands that might be associated to protein aggregates or oligomers, while proteolysis fragments were detected with the anti-Histag monoclonal antibody but not with the polyclonal antibody, indicating a specific C-terminal cleavage. Finally, equivalent protein bands were detected upon tRNA supplementation. According to these results, only a product of approximately 42 kDa and probably other aggregated and degraded protein products, recognized by the monoclonal anti-His-tag and the anti-GLA antibodies, could be obtained in these strains transformed with the pReceiver-B01-GLA expression vector.
In addition, cell fractionation studies performed in E. coli BL21(DE3)/pReceiver-B01-GLA cultures showed that the hGLA produced at different induction temperatures was exclusively detected in the insoluble cell fraction (Suppl. Fig. S2 ).
Recombinant production of mature form of hGLA in E. coli hGLA ORF present in pReceiver-B01-GLA codes for the 429 amino acid hGLA precursor including 31 amino acid residues corresponding to the signal peptide, which is naturally processed in the ER to a 398-amino acids mature form (Lemansky et al. 1987) (Fig. 1b) . Since eukaryotic signal peptides are not processed in prokaryotic hosts, nucleotides coding exclusively for the mature form of the hGLA ORF (32-429; Fig. 1b) were amplified by PCR and transferred to E. coli expression vectors to improve protein folding in the heterologous expression system (Suppl. Fig. S1a , expression vectors a and b). In addition, to promote the formation of disulphide bonds in the hGLA product, the experiments were performed in either Rosetta-gami E. coli strain or the protein was sent to the oxidizing environment present in the periplasm. Expression of the mature form of hGLA in E. coli under these conditions produced aggregated forms of the recombinant protein and protein bands compatible with degradation products (Suppl. Fig. S3 and Suppl. Fig. S4 ).
It has been reported that purification of full-length human proteins can be achieved by fusion to soluble proteins as GST in E. coli (Braun et al. 2002) . This DNA fragment was also inserted into pGEX4T-2, which adds a GST fusion protein at the N-terminal end of the desired protein product (Fig. 1a) .
Protein expression experiments were carried out with transformed Rosetta-gami B(DE3) cells with pGEX4T2-GLA with the aim of using the fused GST for solubilization and purification purposes. Several protein induction conditions were assayed (Suppl. Fig. S5 ). Specific protein bands were detected in all tested conditions in both soluble and insoluble fractions. A predominant band was observed in the insoluble fraction with an apparent weight below 75 kDa that would correspond to the expected GST tagged recombinant hGLA, apart from other protein bands compatible with aggregates and proteolysed forms.
Purification and characterization of the produced human GLA Soluble GST-fused protein was purified by affinity chromatography using a GSTrap HP 1 mL column (GE Healthcare). Elution peak contains highly pure protein sample obtained in one single chromatographic step, indicating that the chosen purification strategy was appropriate (Fig. 3) . However, molecular weight of the purified protein was again smaller than expected. N-terminal sequencing of the protein band demonstrated that corresponded to the initial amino acids of the recombinant protein, although the first methionine was only partially removed. In E. coli, methionine aminopeptidase removes initial methionine with variable efficiency depending on the penultimate amino acid, and it has been demonstrated that the presence of an acidic residue as L present in hGLA reduces its activity up to 20 % (Liao et al. 2004; Xiao et al. 2010a) . Moreover, mass spectrometry of the affinity purified sample revealed that the exact molecular weight of the product was 68.9 kDa (theoretical weight 73.6 kDa). This size reduction in 4.7 kDa is compatible with the elimination of 29 amino acids at the C-terminus of the protein since as it has been demonstrated, the N-terminal end remains intact. Therefore, in this proteolysed hGLA protein, the last amino acid corresponded then to S401 after which an arginine coded by a rare codon has to be added at position 402. In addition, at position 392, another arginine rare codon is present (Fig. 1b) .
On the basis of the above-mentioned results, and to avoid the presence of rare codons close to the proteolytic point of the polypeptide chain, site-directed mutagenesis of the mentioned arginine residues in the hGLA (R402 and R392 rare codons) were performed using the QuikChange Lightning site-directed mutagenesis kit (Stratagene) with oligonucleotides designed by PrimerX (www.Bioinformatics.org). The resulting mutant a b pGEX4T2-GLA (pGEX4T2-GLAmut1; Suppl. Fig. S1a ) was sequenced and used in expression experiments. Western blot analyses of the resulting protein samples showed that a GSThGLA protein could be obtained, but its molecular weight corresponded to the 69-kDa truncated protein previously obtained (data not shown). Further analysis of the RNA sequence of the hGLA revealed the presence of a putative E. coli transcriptional terminator motif surrounding the nucleotide position at which translation seems to finish (Nudler and Gottesman 2002 ) (Suppl. Fig.S1b ). Oligonucleotides were designed to eliminate hairpin loop secondary structures in that region and were used to mutate the pGEX4T2-GLA DNA sequence using the QuikChange Lightning site-directed mutagenesis kit (Stratagene) generating pGEX4T2-GLAmut2 (Suppl. Fig. S1a ). Protein expression experiments showed that under these conditions, the resulting recombinant protein was still truncated, showing an apparent molecular weight of 69 kDa (data not shown). Protein aggregation was observed in protein samples stored at 4°C for 2 weeks and confirmed in Superdex 200 10/300 GL (GE Healthcare) gel filtration chromatography since a protein peak was obtained in the void volume of the column. Activity assays of purified GLA protein fused to GST were performed using purified human GLA from a mammalian expression system as positive control (Corchero et al. 2012) as well as cellular extracts of E. coli cells transformed with pReceiver-B01-GLA and pET22b-GLA but enzymatic activity was not detected in any sample (Table 1) .
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A global codon optimisation of hGLA gene was attempted next. For this purpose, a synthetic GLA gene was designed and constructed (GeneArt; Invitrogen) which was cloned within the pGEX4T2 vector to produce a pGEX4T2-Opt-GLA expression vector with an optimized codon usage ( Fig. 1a, expression vector c) . In that construct, the His-tag purification module was fused at the C-terminus to differentiate from the previous GST-hGLA constructs in which the Histag module was located at the N-terminus of hGLA. The resulting expression vector was used to transform the Rosetta-gami B(DE3) strain. Protein expression experiments of the resulting strain indicated that once again, a truncated protein was produced and hence, production of the intact hGLA does not depend on optimized codon usage (Fig. 4a ).
In addition, the detection of the GST-GLA recombinant protein with anti-GST antibodies demonstrated the presence of GST in the final protein product (Fig. 4b) . However, the same samples were not detected by anti-His antibodies, indicating that truncation of GLA protein occurred at the C-terminus (Fig. 4c) . On the other hand, GST-GLA obtained from the expression of the non-optimized gene contained in pGEX4T2-GLA was detected by both anti-GST and anti-His antibodies since in this construction, His-tag peptide was located Nterminally between the GST and GLA coding sequences (Fig. 1a) .
Since an incomplete product was obtained regardless of the strategies attempted so far, a protease cleavage analysis was carried out using the ExPaSy PeptideCutter program. However, no specific protease cleavage site was found at the C-terminal end of the truncated GLA product obtained. Nevertheless, to confirm these findings, the next attempted strategy was the fusion of another protein (GFP (Hsieh et al. 2010) ) at the C-terminus of the GST-GLA with the aim to protect GLA from a possible proteolysis at this end (Murby et al. 1991) . pGEX4T2-GLA-GFP (Fig. 1a, expression vector  d ) was obtained and transformed into Rosetta-gami B(DE3). Protein expression assays using anti-GLA (Fig. 5a ) and specifically anti-GFP Western blot experiments (Fig. 5b) demonstrated that the whole fused protein GST-His-GLA-GFP could be produced by this strain in contrast to previous experiments. Purification and subsequent TEV proteolysis of the fused protein (Fig. 5c ) did not succeed in producing an active hGLA product despite the strategies attempted (GST and His-tag affinity chromatography), and only background signal was detected when determining the enzymatic activity of the obtained product corresponding to the signal background of the negative control (data not shown).
Recombinant production of mature form of hGLA in P. haloplanktis TAC125 Recombinant P. haloplanktis (pPM13psDs-GLA) cells were aerobically grown in complex rich medium at two different ND not detected temperatures (4 and 15°C), and samples were withdrawn at different times of cultivation. The hGLA production was evaluated by SDS-PAGE followed by Western blotting analysis (using specific anti-GLA polyclonal antibodies) of total soluble protein extracts, and it revealed the highest protein yield after 24 h of cultivation at 15°C (Fig. 6a, b) . No recombinant GLA protein was detected in insoluble protein extracts (data not shown). A cell fractioning followed by Western blotting analysis demonstrated that recombinant GLA produced at higher temperature is also fully localized in the bacterial periplasm (Fig. 6c) , while when produced at 4°C, a fraction of the protein was still associated to the cytoplasm, likely deriving from a less efficient translocation across bacterial inner membrane. Furthermore, at the lower temperature, the recombinant hGLA translocated in the periplasm was also subjected to host encoded proteolytic cleavage, as demonstrated by the appearance of a lower molecular weight specific band on Western blotting analysis shown in Fig. 6c . Soluble protein extracts from P. haloplanktis/pPM13psDs-GLA grown at 15°C for 24 h were used for His-trap affinity purification (His-trap 1 mL column, GE Healthcare) according to the protocol reported in the methods section. A linear gradient was used for elution (20-500 mM imidazole in 15 min at 0.5 mL/min flow), thus obtaining a partial purified protein (about 70 % purity) which has been used for the determination of enzymatic activity (Fig. 6d) . Although the purified enzyme has the tendency to precipitate, it turned out to be active and a value of 77.4±0.3 μmol h −1 mg −1 prot of activity was recorded (Table 1) .
NC C T S I M
Discussion
Recombinant protein production in heterologous expression systems represents a major bottleneck in the development of biopharmaceutical, industrial and research applications (Liras 2008) . Even though high throughput techniques for cloning and protein production have been already described (Barnard et al. 2010; Nettleship et al. 2010; Savitsky et al. 2010; Xiao et al. 2010b) , purification of challenging proteins is still a matter of trial-and-error approaches. As expression system, E. coli offers many advantages over eukaryotic systems referring to rapidity, simplicity and expenditure (Demain and Vaishnav 2009 ). However, it has some disadvantages which, in some cases, are difficult to override as the lack of many posttranslational modifications and high tendency to form aggregated species (Panda 2003) . In the present study, a human full-length protein, GLA, which has been purified from eukaryotic expression systems (Chen et al. 2000a, b; Corchero et al. 2012; Yasuda et al. 2004 ) and non-prokaryotic source (Hantzopoulos and Calhoun 1987) , has been selected to try available expression methods in E. coli and the Antarctica psychrophilic bacterium P. haloplanktis TAC125. In 1987, Hantzopolus and coauthors described the production of an active hGLA in E. coli (Hantzopoulos and Calhoun 1987) . However, such results have not been reproduced or continued since then, and moreover, no purification protocol has been published to date. The interest in developing a production and purification system of human GLA from a prokaryotic source relies on the high cost of the actual enzymatic replacement therapy in Fabry's disease treatment which consists in recombinant protein obtained from mammalian cells having a great economical impact in patient expenditure. We have shown that hGLA can be detected in E. coli as either aggregated and proteolytically cleaved forms in any experimental condition tested. Aggregation of proteins seems to be driven by the presence of specific amino acid sequences (Espargaro et al. 2012) , saturation of the folding machinery (Kolaj et al. 2009) or to the lack of the required posttranslational modifications as glycosylation (Ioannou et al. 1998 ). However, full-length recombinant hGLA has been produced when fused to GST and GFP, although purified protein is not correctly folded lacking biological activity. The absence of enzymatic activity might be related to either unfolded protein species or deletion of the C-terminal end of the protein which seems to be critical (Miyamura et al. 1996) . In addition, GLA has four glycosylation sites added after signal peptide removal in the Golgi apparatus. This sugar moieties (especially glycosylation site located at residue Asn215) play a crucial role in both folding and solubility and consequently in enzymatic activity (Ioannou et al. 1998) . However, when producing hGLA in the psychrophilic expression system based in the use of the Antarctic bacteria P. haloplanktis TAC125, the functional full-length enzyme can be produced and purified. It has been described in comparative studies that recombinant protein production at low temperature has a positive effect in protein yield (Dragosits et al. 2011; Duilio et al. 2004a ) as well as in protein conformation (Vigentini et al. 2006) . The ability of the P. haloplanktis TAC125 to produce active hGLA over the proteolyitic and aggregation tendency of the protein in E. coli might be related to the presence of high peptidyl prolyl cis-trans isomerases genes found in P. haloplanktis TAC125 genome and more specifically to the upregulation of the main molecular chaperone, trigger factor (Giuliani et al. 2014; Piette et al. 2010) . The folding activity in the psychrophilic expression system can counteract the high tendency of the hGLA to adopt unsuitable conformations. On the other hand, in the E. coli cellular environment, the nascent hGLA polypeptides adopt unstable conformational species that are detected by cellular proteases, mainly at the C-terminus of the protein, leading to the formation of inactive aggregation-prone protein species. Even though the full-length protein can be produced in E. coli, the limited chaperone activity in this expression system renders inactive protein. Therefore, b Western blot analysis of the same samples using a polyclonal anti-GLA antibody (Santa Cruz Biotechnology). c Detection of recombinant hGLA in induced P. haloplanktis cell cultures. T, total cell extract; P, periplasm; C, cytoplasm; NC, negative control. d Coomassie blue stained SDS-PAGE of hGLA purification by affinity chromatography. T, total cell extract; 1, unbound protein; 2 and 3, washes; 4, eluted protein microbial host range might be expanded to psychrophilic expression systems when difficult-to-express proteins such as full-length mammalian proteins are to be produced.
